ABCD Nationwide Audits

Since 2004 ABCD has been increasingly active in assessing new diabetes therapies through nationwide audit.  The history of this programme can be viewed on the following link:

ABCD audits of GLP1-receptor agonists

In particular the ABCD nationwide exenatide and liraglutide audits collected real live data on over 13000 patients from over 150 centres with over 500 contributors involved. There have been 12 published papers, 23 abstracts and 13 oral presentations. ABCD also has an ongoing audit of exenatide QW and a nationwide semaglutide audit.

ABCD audits of SGLT2 inhibitors

In the wake of the GLP1-receptor agonist programme, we are now focusing in particular focusing on the SGLT2 class with the nationwide dapagliflozin audit launched in Sept 2014, the canagliflozin audit launched in January 2016 and an empagliflozin audit launched in March 2017.

ABCD FreeStyle Libre Audit

This nationwide audit, our first of a device, launched in November 2017. An online tool was launched in August 2018 and a deadline for first data analysis was set for 14 December 2018.  As of that date we had we had 216 users from 127 sites in 100 centres contributing data on 2869 patients.  Analysis of this data is now ongoing. It is important to stress that was just the first deadline and that the audit continues. It is particularly important that follow up data is submitted as your patients return to see you in the months ahead. For more information and to join the audit click link.

Other current ABCD Nationwide Audits

We have an ongoing audit of insulin degludec and nationwide audit of IDegLira launched in April 2017.